September 29, 2026
Paul S. Links
Envisagez la neuromodulation pour les patients atteints de trouble de la personnalité borderline présentant une dépression majeure comorbide et un échec des antidépresseurs et d'autres médicaments. Les données d'une revue systématique soutiennent un rôle complémentaire dans ces cas. Lors de l'utilisation de la kétamine dans le trouble de la personnalité borderline, surveillez attentivement les...
September 29, 2026
Paul S. Links
Considere a neuromodulação para pacientes com TPB e depressão maior comórbida que não responderam a antidepressivos e outras medicações. Evidências de revisões sistemáticas apoiam um papel complementar nesses casos. Ao utilizar cetamina no TPB, monitore cuidadosamente comportamentos desinibidos e aumento da ideação suicida. Relatos de caso documentaram ambas as reações como efeitos negativos. A...
September 29, 2026
Paul S. Links
Considerare la neuromodulazione per i pazienti con disturbo borderline di personalità e depressione maggiore in comorbilità che non hanno risposto agli antidepressivi e ad altri farmaci. Le evidenze delle revisioni sistematiche supportano un ruolo supplementare in questi casi. Quando si utilizza la ketamina nel disturbo borderline di personalità, monitorare attentamente eventuali comportamenti...
September 29, 2026
Paul S. Links
Consider neuromodulation for BPD patients with comorbid major depression who have failed antidepressants and other medications. Systematic review evidence supports a supplementary role in these cases. When using ketamine in BPD, monitor carefully for disinhibited behaviors and increased suicidal ideation. Case reports have documented both as negative reactions. MDMA-assisted psychotherapy has...
September 29, 2026
Paul S. Links
Overweeg neuromodulatie voor patiënten met borderline persoonlijkheidsstoornis en comorbide majeure depressie bij wie antidepressiva en andere medicatie hebben gefaald. Systematische review-evidentie ondersteunt een aanvullende rol in deze gevallen. Let bij het gebruik van ketamine bij borderline persoonlijkheidsstoornis goed op ontremd gedrag en toegenomen suïcidale ideatie. Casusrapporten...
September 29, 2026
Paul S. Links
Ziehen Sie Neuromodulation bei Patienten mit Borderline-Persönlichkeitsstörung und komorbider Major Depression in Betracht, bei denen Antidepressiva und andere Medikamente versagt haben. Die Evidenz aus systematischen Übersichtsarbeiten stützt eine ergänzende Rolle in diesen Fällen. Achten Sie bei der Anwendung von Ketamin bei Borderline-Persönlichkeitsstörung sorgfältig auf enthemmtes...
September 29, 2026
Paul S. Links
Antidepresanlara ve diğer ilaçlara yanıt vermemiş komorbid majör depresyonu olan BKB hastalarında nöromodülasyonu değerlendirin. Sistematik derleme kanıtları bu vakalarda tamamlayıcı bir rolü desteklemektedir. BKB'de ketamin kullanırken, dezinhibe davranışlar ve artmış intihar düşüncesi açısından dikkatle izleyin. Olgu sunumları her ikisini de olumsuz reaksiyon olarak belgelemiştir. MDMA...
Frontiers in Psychiatry
September 24, 2026
Franziska Stadler, Johan Saelens, Ioline D. Henter et al.
Background: The past few decades have seen a revived interest in psychedelic-assisted and ketamine-assisted therapy for mental health disorders, but data concerning the acute, subacute, and long-term effects of serotonergic psychedelics on cognitive functioning are scarce. This international, online study (N = 759) sought to investigate the potential acute, subacute, and long-term effects of...
Clinical Neuropsychopharmacology and Addiction
September 24, 2026
Giacomo D’andrea, Antonio Inserra, Andrea Miuli et al.
While psychedelic experiences are often reported as positive, adverse psychological reactions can occur. We present the case of a 19-year-old Caucasian male who presented to the ER with suicidal thoughts after taking lysergic acid diethylamide (LSD) alone. He was diagnosed with anxious state associated with panic attacks, and suicidal thoughts without ideation or behaviors. He was admitted to...
npj Mental Health Research
September 22, 2026
Ramūnas Janavičius
The letter addresses critical issues in the methodology and conclusions of the meta-analysis, including inconsistencies in study design, methodological flaws in comparing correlation coefficients, and discrepancies in reported results and their interpretation. It contributes significantly to the ongoing discussion on psychedelic-assisted therapies and highlights the need for more standardized...